Pharmacotherapy of Child and Adolescent Psychiatric Disorders Ebook Tooltip

Afbeeldingen

Inkijkexemplaar

Artikel vergelijken

  • Engels
  • E-book
  • 9781119961000
  • 22 november 2011
  • 456 pagina's
  • Adobe ePub
Alle productspecificaties
  • Je leest ebooks gemakkelijk op je Kobo e-reader, of op je smartphone of tablet met de bol.com Kobo app. Let op! Ebooks kunnen niet geannuleerd of geretourneerd worden.

Samenvatting

This book fulfils an urgent need for an updated text on pediatric psychopharmacology. It takes a unique approach in discussing recent findings within the context of current issues, including economic and political ones. The book covers the emerging question of treating children who do not yet meet diagnostic criteria for psychosis, e.g, schizophrenia or bipolar disorder, but who are deemed to be at high risk. This is an active area of debate: such children are being treated in certain centers, while others reject this completely. The book addresses the antidepressant controversy, the placebo response and unique strategies for delineating this, and ways to optimize the differential between active medication and placebo. It reviews the impact of recent American Heart Association guidelines for monitoring children on stimulants and other psychotropics. It adheres closely to DSM-IV diagnostic criteria throughout. The book describes the use of newly approved drugs such as Lexapro for treating adolescent depression and the novel compound Intuniv. It covers the TADS and CAMS studies, which evaluated the use of SSRIs alone and in combination with cognitive behavioral therapy for adolescent depression. Other topics include treatment of bipolar disorders, the increasing popularity of generic equivalents, combination pharmacotherapy and the potential dangers of psychotropic medications.bulletThird edition of the first ever book published on pediatric psychopharmacology from renowned editors.bulletIncorporates current developments with regard to SSRIs, their indications and their safety issues, including possible associated suicidal behavior.bulletAddresses concerns about cardiovascular side effects of the new stimulant medications available, and compares to other FDA-approved medications for ADHD.bulletFeatures many tables, figures and pictorials, making it highly accessible and reader friendly./bulletlist

Productspecificaties

Inhoud

Taal
en
Bindwijze
E-book
Oorspronkelijke releasedatum
22 november 2011
Aantal pagina's
456
Ebook Formaat
Adobe ePub
Illustraties
Nee

Betrokkenen

Hoofdauteur
D Rosenberg
Tweede Auteur
Samuel Gershon
Hoofdredacteur
David Rosenberg
Tweede Redacteur
Samuel Gershon
Hoofduitgeverij
Wiley-Blackwell

Lees mogelijkheden

Lees dit ebook op
Android (smartphone en tablet) | Kobo e-reader | Desktop (Mac en Windows) | iOS (smartphone en tablet) | Windows (smartphone en tablet)

Overige kenmerken

Editie
3
Extra groot lettertype
Nee
Studieboek
Nee
Verpakking breedte
175 mm
Verpakking hoogte
27 mm
Verpakking lengte
248 mm
Verpakkingsgewicht
854 g

EAN

EAN
9781119961000

Je vindt dit artikel in

Taal
Engels
Beschikbaarheid
Leverbaar
Boek, ebook of luisterboek?
Ebook
Nog geen reviews

Kies gewenste uitvoering

Prijsinformatie en bestellen

De prijs van dit product is 80 euro en 99 cent.
Direct beschikbaar
Verkoop door bol
  • E-book is direct beschikbaar na aankoop
  • E-books lezen is voordelig
  • Dag en nacht klantenservice
  • Veilig betalen
Houd er rekening mee dat je downloadartikelen niet kunt annuleren of retourneren. Bij nog niet verschenen producten kun je tot de verschijningsdatum annuleren.
Zie ook de retourvoorwaarden

Lijst met gekozen artikelen om te vergelijken

Vergelijk artikelen